A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms RELAX-AHF-ASIA
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2017 Status changed from recruiting to discontinued.
    • 06 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
    • 06 Jun 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top